IL13 and idiopathic pulmonary fibrosis: A phase 2, randomised, double-blind, placebo-controlled trial that assessed change in % predicted FVC at 72 weeks of the anti–IL-13 tralokinumab in 302 patients with IPF was terminated due to lack of efficacy after the interim analysis [27].